Lynx1 Capital Management LP Increases Stake in Neuphoria Therapeutics Inc.

Lynx1 Capital Management LP has significantly increased its stake in Neuphoria Therapeutics Inc., acquiring 875,328 shares of common stock, representing a 37.1% ownership in the company. The total value of the shares acquired is approximately $4,524,327. The investment was made because Lynx1 Capital Management LP believes the securities are undervalued and represent an attractive investment opportunity. The firm may engage in discussions with the company's management and board regarding operations, management, and strategic plans. Lynx1 Capital Management LP may also consider increasing or decreasing its position in the company based on various factors, including market conditions and the company's financial position. The filing includes details of transactions made over the past sixty days, with the majority of shares purchased on October 21, 2025, at a weighted average price of $5.0883 per share.